Your browser doesn't support javascript.
loading
Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy-case report.
Schiopu, Sanziana R I; Käsmann, Lukas; Schönermarck, Ulf; Fischereder, Michael; Grabmaier, Ulrich; Manapov, Farkhad; Rauch, Josefine; Orban, Martin.
Afiliação
  • Schiopu SRI; Intensive Care Unit, Medical Clinic I, Ludwig Maximilian University Munich, Munich, Germany.
  • Käsmann L; Department of Cardiology, DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
  • Schönermarck U; Department of Radiation Oncology, University Hospital, Ludwig Maximilian University Munich, Munich, Germany.
  • Fischereder M; Comprehensive Pneumology Center Munich (CPC-M), Munich, Germany.
  • Grabmaier U; Medical Clinic IV, Ludwig Maximilian University Munich, Munich, Germany.
  • Manapov F; Medical Clinic IV, Ludwig Maximilian University Munich, Munich, Germany.
  • Rauch J; Intensive Care Unit, Medical Clinic I, Ludwig Maximilian University Munich, Munich, Germany.
  • Orban M; Department of Cardiology, DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
Transl Lung Cancer Res ; 10(2): 1039-1046, 2021 Feb.
Article em En | MEDLINE | ID: mdl-33718042
ABSTRACT
Malignant mesothelioma is an aggressive cancer associated with prior exposure to asbestos and dismal prognosis. Immune checkpoint inhibitor therapy is currently approved by the Food and Drug Administration for pre-treated malignant pleural mesothelioma. We describe a 75-year-old patient with disseminated, progressive malignant mesothelioma receiving 2 cycles of pembrolizumab who presented with generalized muscle weakness, shortness of breath, double vision and ptosis. There was no previous history of cardiovascular disease. The clinical picture, supported by the detection of anti-titin autoantibodies suggested myasthenia gravis (MG). Also, cardiac biomarkers were elevated. Echocardiography showed new severely reduced ejection fraction. A 12-lead resting electrocardiogram (ECG) revealed ST segment elevation in the posterior leads with polymorphic ventricular extrasystoles. Because cardiac catheterization revealed no relevant coronary lesions, immune checkpoint inhibitor-associated myocarditis and MG were suspected. Management and

Outcome:

The patient was started on steroids. Within a few days of presentation respiratory failure set in and the patient was intubated. Recurrent arrhythmias followed, which were treated by repeated emergency electrical cardioversion. In order to relieve myasthenic symptoms, plasma exchange was initiated and 10 cycles were carried out. This consequently also led to an improvement of myocarditis. Upon discharge, the ejection fraction recovered. The patient recovered and was alive at 1-year follow-up, without relevant limitations to his quality of life. Discussion and

Conclusion:

The article further discusses the use of plasma exchange for immune checkpoint inhibitor-associated myocarditis based on a review of literature. We conclude that patients showing no improvement after steroid therapy for immune checkpoint inhibitor-related myocarditis should be evaluated for plasma exchange, which appears to be an effective treatment option.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha